Amwell® to report fourth quarter and full year 2025 operating results
Rhea-AI Summary
Amwell (NYSE: AMWL) will report fourth quarter and full year 2025 operating results after market close on Thursday, Feb. 12, 2026. Management will host a live conference call and webcast at 5:00 p.m. ET to review results and provide a business update.
The full earnings release and live audio webcast will be available in the company's Investors section; a webcast replay will remain available at investors.amwell.com for approximately 90 days.
Positive
- None.
Negative
- None.
Key Figures
Market Reality Check
Peers on Argus
AMWL is up 1.38% while several close peers like CCLD (-4.31%), HCAT (-0.46%), SOPH (-1.38%) and MNDR (-3.07%) are down, indicating stock-specific factors rather than a sector-wide move.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Nov 04 | Q3 2025 earnings | Neutral | -0.8% | Reported Q3 2025 financial results and hosted earnings call webcast. |
| Oct 27 | Q3 earnings date | Neutral | -3.3% | Announced Q3 2025 earnings release timing and upcoming investor conferences. |
| Aug 08 | Inducement RSU grants | Neutral | -1.5% | Granted 76,198 RSUs to new employees under inducement plan. |
| Aug 05 | Q2 2025 earnings | Neutral | -7.3% | Announced Q2 2025 financial results and scheduled related earnings call. |
| Aug 05 | Defense contract extension | Positive | +20.4% | Extended Digital First contract supporting Military Health System digital care. |
Recent earnings-related announcements (Q2 and Q3 results and the Q3 earnings date) were followed by negative 24-hour moves, while a major government contract extension drew a strong positive reaction.
Over the last six months, AMWL has mainly reported earnings and contract developments. Announcements of Q2 2025 and Q3 2025 results, plus the Q3 2025 earnings-date notice, all saw modest to moderate single-day declines. A contract extension to support the U.S. Defense Health Agency and Military Health System on Aug 05, 2025 coincided with a 20.45% gain, standing out as a key operational milestone. Today’s earnings-date release for Q4 and full-year 2025 fits that pattern of routine scheduling updates.
Market Pulse Summary
This announcement sets the timing for Amwell’s Q4 and full-year 2025 report on Feb. 12, with a conference call at 5 p.m. ET and a webcast replay available for 90 days. Historically, earnings-related updates in Q2 and Q3 2025 were followed by short-term share price declines, while a major Defense Health Agency contract extension produced a strong gain. Investors may focus on how new results relate to these prior operational milestones and the longer-term trend.
Key Terms
saas-based technical
webcast technical
AI-generated analysis. Not financial advice.
BOSTON, Feb. 05, 2026 (GLOBE NEWSWIRE) -- Amwell® (NYSE: AMWL), a leading provider of a comprehensive SaaS-based software platform for technology-enabled healthcare, will report fourth quarter and full year 2025 operating results after stock market trading hours on Thursday, Feb. 12.
Following the distribution of the earnings alert via wire services, the Amwell management team will host a live conference call and webcast at 5 p.m. ET to review the company's operating results and provide a general business update.
The full earnings report and the live audio webcast can be accessed by visiting the Investors section of the company's website. A webcast replay of the call will be available at investors.amwell.com for approximately 90 days.
About Amwell
Amwell offers payers and health systems a single, comprehensive, technology-enabled care platform. We use technology to provide patients with better access to more convenient, affordable and effective care. The Amwell platform includes software and services that power many clinical programs from Amwell and our growing number of partners. Our platform allows patients to experience unified, personalized and simple access to diversified clinical programs across the care continuum. As more people seek care online and more clinical programs become available, we offer integrated, future-ready, consistent solutions. The Amwell platform is proven, operating at a large scale, enabling care for millions of patients and their sponsors while delivering dependable outcomes. For almost two decades, Amwell has proudly served some of the largest and most sophisticated healthcare organizations in the U.S. and worldwide. For more information, visit business.amwell.com or LinkedIn.
Investors:
Asher Dewhurst
Media: